Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Steve Wedge

Newcastle AuthorsTitleYearFull text
Stephanie Myers
Duncan Miller
Dr Lauren Molyneux
Dr Mercedeh Arasta
Dr Ruth Bawn
et al.
Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD42019
Dr Catherine Willoughby
Huw Thomas
Dr Elaine Willmore
Suzanne Kyle
Dr Anita Wittner
et al.
Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy2019
Professor Ruth Plummer
Professor Steve Wedge
Professor Gareth Veal
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours2018
Honorine Lebraud
Dr Richard Noble
Nicole Phillips
Dr Yan Zhao
Emeritus Professor Herbie Newell
et al.
A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition2018
Duncan Miller
Dr Mathew Martin
Santosh Adhikari
Alfie Brennan
Professor Jane Endicott
et al.
Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach2018
Dr Celine Cano
Dr Suzannah Harnor
Dr Elaine Willmore
Professor Steve Wedge
Targeting DNA-PK as a Therapeutic Approach in Oncology2018
Professor Steve Wedge
Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib2017
Professor Steve Wedge
A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer2017
Lucy Gentles
Dr Calum Kirk
Huw Thomas
Professor Steve Wedge
Professor Nicola Curtin
et al.
An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer2017
Dr Dominic Jones
Professor Martin Noble
Professor Steve Wedge
Professor Craig Robson
Dr Luke Gaughan
et al.
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer2017